<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428622</url>
  </required_header>
  <id_info>
    <org_study_id>1249.7</org_study_id>
    <secondary_id>2011-000935-98</secondary_id>
    <nct_id>NCT01428622</nct_id>
  </id_info>
  <brief_title>Olodaterol Bridging Study in Asthma</brief_title>
  <official_title>Single Dose Comparison of 3 Doses of Olodaterol in Double Fixed Dose Combination With BI54903 vs. 3 Doses of Olodaterol Mono in Free Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to establish the olodaterol dose in the ethanolic fixed dose
      combination (FDC) with BI 54903 which is equivalent in bronchodilator effect and systemic
      exposure to the 5 Âµg olodaterol reference dose in the aqueous inhalation solution (AIS).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2011</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 (AUC0-12h) FEV1 = Forced expiratory volume in one second, AUC = area under the curve</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 (AUC0-24h)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (AUC12-24h)</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo + BI 54903</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive 2 puffs of respimat &quot;A&quot; and 2 puffs of respimat &quot;B&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol low dose + BI54903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 puffs of respimat &quot;A&quot; and 2 puffs of respimat &quot;B&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol medium dose + BI54903</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive 2 puffs of each device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol high dose + BI54903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 puffs of each device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol l dose + BI54903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 puffs of each device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol m dose + BI54903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 puffs of each device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol h dose + BI54903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive 2 puffs of each device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Placebo + BI 54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol low dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol medium dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol high dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol l dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol m dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>aqueous and ethanolic solution</description>
    <arm_group_label>Olodaterol h dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Placebo + BI 54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol low dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol medium dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol high dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol l dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol m dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <description>aqueous solution</description>
    <arm_group_label>Olodaterol h dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Placebo + BI 54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol low dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol medium dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol high dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol l dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol m dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol &amp; BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol h dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Placebo + BI 54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol low dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol medium dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol high dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol l dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol m dose + BI54903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI54903</intervention_name>
    <description>ethanolic solution</description>
    <arm_group_label>Olodaterol h dose + BI54903</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Informed Consent Form consistent guidelines and local legislation prior

          2. Male or female patients aged at least 18 to 75 years.

          3. Diagnosis of asthma according to the 2009 Global Initiative for Asthma (GINA)
             Guidelines.

          4. Maintenance treatment with a low or medium dose of inhaled corticosteroids (ICS) with
             or without Long-acting beta-adrenergic (LABA), stable dose of inhaled corticosteroids
             (alone or in a fixed combination with a LABA) for at least for 6 weeks prior to
             screening.

          5. Asthma control questionaire (ACQ)-6 mean score of &lt; 1.5.

          6. a. Pre-bronchodilator clinic measured FEV1 =50% and =90% of predicted normal b. FEV1
             reversibility: Improvement in FEV1 =12% above baseline and an absolute change of at
             least 200 ml within 15-30 minutes after administration of 400 Âµg salbutamol.

          7. Never-smokers or ex-smokers with a smoking history of less than 10 pack-years and
             smoking cessation at least one year prior to screening.

          8. Be able to use the inhalers correctly in the opinion of the investigator.

          9. Be able to perform all trial related procedures.

        Exclusion criteria:

          1. Significant disease other than asthma.

          2. Recent history (i.e. six months or less) of myocardial infarction.

          3. Hospitalisation for cardiac failure during the past year.

          4. Unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring
             intervention or a change in drug therapy within the past year.

          5. Lung diseases other than asthma (e.g. Chronic obstructive pulmonary disease).

          6. Active tuberculosis.

          7. Malignancy for which the patient has undergone resection, radiation therapy or
             chemotherapy within the last five years.

          8. Thoracotomy with pulmonary resection.

          9. Alcohol or drug abuse within the past two years.

         10. Pulmonary rehabilitation program

         11. Hypersensitivity to LABA drugs, ciclesonide, salmeterol or any other components of the
             study medication delivery systems.

         12. Pregnant or nursing woman.

         13. Women of childbearing potential not using a highly effective method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1249.7.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>GiÃ¨res</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Romania</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

